Preparation and application of cytokine fusion antibody

A technology of fusing antibodies and growth factor receptors, applied in the field of bioengineering, can solve the problems of strong systemic toxic and side effects, inability to reduce systemic toxic and side effects well, and short interferon half-life.
CN106065033AInactive Publication Date: 2016-11-02CHINA PHARM UNIV
4 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHINA PHARM UNIV
Publication Date
2016-11-02
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Belonging to the technical field of genetic engineering antibodies, the invention specifically discloses a vascular endothelial growth factor receptor 2 (VEGFR2 or KDR) targeted fusion antibody JZA01of antibody JZB00 and interferon alpha (IFN alpha), a preparation method and application thereof. The invention also discloses the amino acid sequences of heavy chain and light chain immunoglobulin molecules of JZA01. The invention also provides a construction method of JZA01 heavy chain and light chain gene, CHO cells are transfected, monoclone is picked by limited dilution method, then by means of eukaryotic cell secretory expression and affinity chromatography purification, the fusion antibody can be obtained. The fusion antibody provided by the invention can specifically bind VEGFR2 and inhibit tumor angiogenesis, the coupled interferon part also can also play a direct tumor killing and immunoregulation role, and no toxic or side effect is generated at the same time, thereby better inhibiting tumor growth. The fusion antibody can inhibit the proliferation of human umbilical vein endothelial cells (HUVEC) and some tumor cells in vitro.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of bioengineering, and specifically relates to a high-affinity fully human fusion antibody that can specifically bind to human VEGFR2. Genes, using flexible peptides to connect two pieces of protein. On the one hand, the antibody can inhibit the activation of human vascular endothelial growth factor receptor 2, thereby inhibiting the formation of tumor angiogenesis; It has immunoregulatory effect and does not produce toxic and side effects. It is a genetically engineered antibody with anti-angiogenesis and anti-tumor activities. Background technique

[0002] The occurrence and development of tumor cells is inseparable from the nutrient supply of new blood vessels, and the growth of new blood vessels is inseparable from the interaction of various cytokines and their receptors. Existing studies have shown that the vascular endothelial growth factor / vascular endothelial growth factor receptor (VEGF / VEGFR) signaling pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More